Table 3 Cox regression analysis for HCC in total patients.

From: Comparison of hepatocellular carcinoma incidence after long-term treatment with besifovir vs. tenofovir AF

 

Univariate

Multivariate

HR (95% CI)

P

HR (95% CI)

P

Antiviral medication

 BSV

1 (ref)

 

1 (ref)

 

 TAF

1.18 (0.87–1.60)

0.285

1.14 (0.84–1.55)

0.413

Age (years)

1.05 (1.04–1.06)

< 0.001

1.05 (1.03–1.06)

< 0.001

Male

2.10 (1.56–2.83)

< 0.001

2.77 (2.05–3.76)

< 0.001

Duration of antiviral medication (days)

1.00 (1.00–1.00)

0.001

1.00 (1.00–1.00)

< 0.001

Diabetes

1.92 (1.47–2.50)

< 0.001

1.05 (0.80–1.39)

0.723

CCI score

1.19 (1.09–1.31)

< 0.001

0.99 (0.88–1.10)

0.802

Presence of cirrhosis

3.30 (2.55–4.26)

< 0.001

1.51 (1.12–2.04)

0.007

Presence of decompensation

7.30 (5.59–9.52)

< 0.001

4.71 (3.43–6.46)

< 0.001

  1. HR hazard ratio, CI confidence interval, BSV besifovir dipivoxil maleate, TAF tenofovir alafenamide, CCI Charlson comorbidity index.
Back to article page